[18F]-sodium fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial.


Journal

The spine journal : official journal of the North American Spine Society
ISSN: 1878-1632
Titre abrégé: Spine J
Pays: United States
ID NLM: 101130732

Informations de publication

Date de publication:
05 2022
Historique:
received: 06 03 2021
revised: 21 11 2021
accepted: 22 11 2021
pubmed: 2 12 2021
medline: 11 5 2022
entrez: 1 12 2021
Statut: ppublish

Résumé

[18F]-sodium fluoride (NaF) PET/MR is a modern diagnostic modality for imaging increased bone turnover. Its merits in detecting painful facet joint osteoarthritis in patients with lumbar back pain are unknown. To perform a prospective randomized controlled study investigating [18F]-NaF PET/MR for detecting painful facet joints in comparison to the standard of care (SOC), including clinical examination and conventional MRI. Randomized controlled clinical study. Thirty-nine patients. Visual analog pain scale (VAS) before and at several time points after facet joint infiltration. Patients with low back pain and suspected facet joint osteoarthritis underwent lumbar [18F]-NaF PET/MR, besides conventional MRI and clinical examination. After randomization, they either received local anesthetics/ corticosteroid infiltration of facet joints as defined by clinical examination and conventional MRI (SOC), or according to the hot spots on PET/MR. VAS was documented at 15 minutes, 1 day, 1 week and 1 month after infiltration. Thirty-nine patients underwent PET/MR before the study was stopped due to new Good Manufacturing Practice requirement and new regulations by radiation protection authorities limiting staff radiation exposure during the production of this radiotracer. Significant pain reduction compared to baseline was shown at every timepoint in both groups, except at 1 month after infiltration in the SOC group. Pain levels did not differ between SOC (n=17) and PET/MR patients (n=12) before infiltration and at 15 minutes, 1 day, 1 week and 1 month after infiltration. No significant correlation was detected between the sum of the PET/MR activity and the initial pain scores or relative reduction of pain after 15 minutes. The constructed study groups of patients with infiltration of all facet joints being PET/MR-positive (n=18) had significantly less pain after 1 months than patients with infiltration in PET/MR-negative facet joints (n=11) (VAS: 4 [0, 9] vs. 7 [2, 10], p=.046). There is no correlation of pain to NaF activity nor a relevant superiority of [18F]-NaF PET/MR for identification of painful facet joints compared to the standard of care.

Sections du résumé

BACKGROUND CONTEXT
[18F]-sodium fluoride (NaF) PET/MR is a modern diagnostic modality for imaging increased bone turnover. Its merits in detecting painful facet joint osteoarthritis in patients with lumbar back pain are unknown.
PURPOSE
To perform a prospective randomized controlled study investigating [18F]-NaF PET/MR for detecting painful facet joints in comparison to the standard of care (SOC), including clinical examination and conventional MRI.
STUDY DESIGN/SETTING
Randomized controlled clinical study.
PATIENT SAMPLE
Thirty-nine patients.
OUTCOME MEASURES
Visual analog pain scale (VAS) before and at several time points after facet joint infiltration.
METHODS
Patients with low back pain and suspected facet joint osteoarthritis underwent lumbar [18F]-NaF PET/MR, besides conventional MRI and clinical examination. After randomization, they either received local anesthetics/ corticosteroid infiltration of facet joints as defined by clinical examination and conventional MRI (SOC), or according to the hot spots on PET/MR. VAS was documented at 15 minutes, 1 day, 1 week and 1 month after infiltration. Thirty-nine patients underwent PET/MR before the study was stopped due to new Good Manufacturing Practice requirement and new regulations by radiation protection authorities limiting staff radiation exposure during the production of this radiotracer.
RESULTS
Significant pain reduction compared to baseline was shown at every timepoint in both groups, except at 1 month after infiltration in the SOC group. Pain levels did not differ between SOC (n=17) and PET/MR patients (n=12) before infiltration and at 15 minutes, 1 day, 1 week and 1 month after infiltration. No significant correlation was detected between the sum of the PET/MR activity and the initial pain scores or relative reduction of pain after 15 minutes. The constructed study groups of patients with infiltration of all facet joints being PET/MR-positive (n=18) had significantly less pain after 1 months than patients with infiltration in PET/MR-negative facet joints (n=11) (VAS: 4 [0, 9] vs. 7 [2, 10], p=.046).
CONCLUSIONS
There is no correlation of pain to NaF activity nor a relevant superiority of [18F]-NaF PET/MR for identification of painful facet joints compared to the standard of care.

Identifiants

pubmed: 34848344
pii: S1529-9430(21)01048-2
doi: 10.1016/j.spinee.2021.11.014
pii:
doi:

Substances chimiques

Sodium Fluoride 8ZYQ1474W7

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

769-775

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

José Miguel Spirig (JM)

Spine Division, Balgrist University Hospital, University of Zurich, Forchstrasse 340, Zurich 8008, Switzerland. Electronic address: jose.spirig@balgrist.ch.

Martin Hüllner (M)

Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, Zurich 8091, Switzerland.

Frédéric Cornaz (F)

Spine Division, Balgrist University Hospital, University of Zurich, Forchstrasse 340, Zurich 8008, Switzerland.

Michael Betz (M)

Spine Division, Balgrist University Hospital, University of Zurich, Forchstrasse 340, Zurich 8008, Switzerland.

Florian Wanivenhaus (F)

Spine Division, Balgrist University Hospital, University of Zurich, Forchstrasse 340, Zurich 8008, Switzerland.

Marlena Hofbauer (M)

Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, Zurich 8091, Switzerland.

Anass Johayem (A)

Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, Zurich 8091, Switzerland.

Philipp A Kaufmann (PA)

Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, Zurich 8091, Switzerland.

Mazda Farshad (M)

Spine Division, Balgrist University Hospital, University of Zurich, Forchstrasse 340, Zurich 8008, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH